U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H28N2O3.ClH
Molecular Weight 368.898
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SONLICROMANOL HYDROCHLORIDE

SMILES

Cl.CC1=C(C)C2=C(CC[C@](C)(O2)C(=O)N[C@@H]3CCCNC3)C(C)=C1O

InChI

InChIKey=HVFWCHDZDIRYBZ-MQZJHDQISA-N
InChI=1S/C19H28N2O3.ClH/c1-11-12(2)17-15(13(3)16(11)22)7-8-19(4,24-17)18(23)21-14-6-5-9-20-10-14;/h14,20,22H,5-10H2,1-4H3,(H,21,23);1H/t14-,19+;/m1./s1

HIDE SMILES / InChI

Description

KH-176 is a drug candidate developed by pharmaceutical company Khondrion to treat a range of mitochondrial diseases including MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders. KH176 has been granted Orphan Drug Designation for MELAS spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the USA. KH176 acts as a potent intracellular redox-modulating agent essential for the control of oxidative and redox pathologies.

Approval Year

Unknown
149124
PubMed

PubMed

TitleDatePubMed
The KHENERGY Study: Safety and Efficacy of KH176 in Mitochondrial m.3243A>G Spectrum Disorders.
2019-01
Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh Disease.
2017-09-15
Name Type Language
KH-176 HYDROCHLORIDE
Preferred Name English
SONLICROMANOL HYDROCHLORIDE
Common Name English
(2S)-6-HYDROXY-2,5,7,8-TETRAMETHYL-N-((3R)-3-PIPERIDYL)CHROMANE-2-CARBOXAMIDE HYDROCHLORIDE
Systematic Name English
KH-176(HYDROCHLORIDE)
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/15/1543
Created by admin on Mon Mar 31 22:17:04 GMT 2025 , Edited by admin on Mon Mar 31 22:17:04 GMT 2025
FDA ORPHAN DRUG 450714
Created by admin on Mon Mar 31 22:17:04 GMT 2025 , Edited by admin on Mon Mar 31 22:17:04 GMT 2025
Code System Code Type Description
EU-Orphan Drug
EU/3/14/1336(POSITIVE)
Created by admin on Mon Mar 31 22:17:04 GMT 2025 , Edited by admin on Mon Mar 31 22:17:04 GMT 2025
PRIMARY On 15 October 2014, orphan designation (EU/3/14/1336) was granted by the European Commission to Khondrion BV, the Netherlands, for (S)-6-Hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3?yl)chroman-2-carboxamide hydrochloride for the treatment of Leigh syndrome.
EU-Orphan Drug
EU/3/15/1543(POSITIVE)
Created by admin on Mon Mar 31 22:17:04 GMT 2025 , Edited by admin on Mon Mar 31 22:17:04 GMT 2025
PRIMARY On 10 August 2015, orphan designation (EU/3/15/1543) was granted by the European Commission to Khondrion BV, the Netherlands, for (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes.
FDA UNII
858M8246UL
Created by admin on Mon Mar 31 22:17:04 GMT 2025 , Edited by admin on Mon Mar 31 22:17:04 GMT 2025
PRIMARY
SMS_ID
100000180594
Created by admin on Mon Mar 31 22:17:04 GMT 2025 , Edited by admin on Mon Mar 31 22:17:04 GMT 2025
PRIMARY
PUBCHEM
72710874
Created by admin on Mon Mar 31 22:17:04 GMT 2025 , Edited by admin on Mon Mar 31 22:17:04 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of SONLICROMANOL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966